Hypoxia contributes to radiotherapy resistance and more aggressive behaviour of several types of cancer. This study was designed to evaluate the repeatability of intratumour uptake of the hypoxia tracer [18F]EF5 in paired PET/CT scans.
Ten patients with newly diagnosed head and neck cancer (HNC) received three static PET/CT scans before chemoradiotherapy: two with [18F]EF5 a median of 7 days apart and one with [18F]FDG. Metabolically active primary tumour volumes were defined in [18F]FDG images and transferred to co-registered [18F]EF5 images for repeatability analysis. A tumour-to-muscle uptake ratio (TMR) of 1.5 at 3 h from injection of [18F]EF5 was used as a threshold representing hypoxic tissue.
In 10 paired [18F]EF5 PET/CT image sets, SUVmean, SUVmax, and TMR showed a good correlation with the intraclass correlation coefficients of 0.81, 0.85, and 0.87, respectively. The relative coefficients of repeatability for these parameters were 15%, 17%, and 10%, respectively. Fractional hypoxic volumes of the tumours in the repeated scans had a high correlation using the Spearman rank correlation test (r = 0.94). In a voxel-by-voxel TMR analysis between the repeated scans, the mean of Pearson correlation coefficients of individual patients was 0.65. The mean (± SD) difference of TMR in the pooled data set was 0.03 ± 0.20.
Pretreatment [18F]EF5 PET/CT within one week shows high repeatability and is feasible for the guiding of hypoxia-targeted treatment interventions in HNC.
Welz S, Mönnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougère C, et al. Prognostic value of dynamic hypoxia PET in head and neck cancer: results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol. 2017;124:526–32. CrossRefPubMed
Komar G, Lehtiö K, Seppänen M, Eskola O, Levola H, Lindholm P, et al. Prognostic value of tumour blood flow, [ 18F]EF5 and [ 18F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. Eur J Nucl Med Mol Imaging. 2014:2042–50.
Minn H, Suilamo S, Seppälä J. Impact of PET/CT on planning of radiotherapy in head and neck cancer. Q J Nucl Med Mol Imaging. 2010;54:521–32. PubMed
Silvoniemi A, Silén J, Forsback S, Löyttyniemi E, Schrey AR, Solin O, et al. Evaluation of repeated [ 18F]EF5 PET/CT scans and tumor growth rate in experimental head and neck carcinomas. EJNMMI Res. 2014;4:65.
Bollineni VR, Koole MJ, Pruim J, Brouwer CL, Wiegman EM, Groen HJ, et al. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother Oncol. 2014;113:198–203. CrossRefPubMed
Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Trans-Tasman radiation oncology group study 98.02. Prognostic significance of [ 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-Tasman radiation oncology group study 98.02. J Clin Oncol. 2006;24:2098–104. CrossRefPubMed
- Repeatability of tumour hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer
Tove J. Grönroos
- Springer Berlin Heidelberg
European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089